H.C. Wainwright lowered the firm’s price target on Rhythm Pharmaceuticals (RYTM) to $110 from $125 and keeps a Buy rating on the shares, reflecting adjustments to the firm’s long-term sales ramp expectations after Rhythm recently announced its Q4 results and announced additional positive data from its global Phase 3 TRANSCEND trial of setmelanotide in patients with acquired hypothalamic obesity.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RYTM:
- Rhythm Highlights Positive Phase 3 Data in Hypothalamic Obesity
- Rhythm Pharmaceuticals price target lowered to $140 from $141 at Canaccord
- Rhythm announces additional data from Phase 3 trial of setmelanotide
- Rhythm Pharmaceuticals price target raised to $143 from $140 at Guggenheim
- Rhythm Pharmaceuticals price target lowered to $136 from $145 at Wells Fargo